Early experience with remdesivir in SARS-CoV-2 pneumonia.

Link to article at PubMed

Related Articles

Early experience with remdesivir in SARS-CoV-2 pneumonia.

Infection. 2020 May 16;:

Authors: Durante-Mangoni E, Andini R, Bertolino L, Mele F, Florio LL, Murino P, Corcione A, Zampino R

At present, there is no definitive antiviral treatment for coronavirus disease 2019 (COVID-19). We describe our early experience with remdesivir in four critically ill COVID-19 patients. Patients received a 200 mg loading dose, followed by 100 mg daily intravenously for up to 10 days. All patients had been previously treated with other antivirals before remdesivir initiation. One patient experienced a torsade de pointes requiring cardiac resuscitation and one died due to multiple organ failure. Three patients showed biochemical signs of liver injury. Lymphocyte count increased in all patients soon after remdesivir initiation. Nasal swab SARS-CoV-2 RNA became negative in three of four patients after 3 days of therapy. We observed an in vivo virological effect of remdesivir in four critically ill, COVID-19 patients, coupled with a significant burden of adverse events. Although limited by the low number of subjects studied, our preliminary experience may be relevant for clinicians treating COVID-19.

PMID: 32418190 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.